Down-regulation of vasoactive intestinal peptide and altered expression of its receptors in rat diabetic cardiomyopathy

Cell and Tissue Research

Volumn 323, Issue 3, 2006, Pages 383-393

  Dvoráková, Magdalena Chottová ^a   Pfeil, Uwe ^b   Kuncová, Jitka ^a   Švíglerová, Jitka ^a   Galvis, Giovanni ^b   Krasteva, Gabriela ^b   König, Peter ^b   Grau, Veronika ^b   Slavíková, Jana ^a   Kummer, Wolfgang ^b  

^a CHARLES UNIVERSITY   (Czech Republic)

^b JUSTUS LIEBIG UNIVERSITY   (Germany)

Author keywords

Autonomic neuropathy; Cardiac ganglia; Cardiac innervation; Diabetes; Heart; Rat (Wistar)

Indexed keywords

MESSENGER RNA; PROTEIN VPAC1; PROTEIN VPAC2; RECEPTOR SUBTYPE; STREPTOZOCIN; UNCLASSIFIED DRUG; VASOACTIVE INTESTINAL POLYPEPTIDE; VASOACTIVE INTESTINAL POLYPEPTIDE RECEPTOR;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ARTERIOLE; ARTICLE; CARDIOMYOPATHY; CONTROLLED STUDY; DIABETIC NEUROPATHY; DOWN REGULATION; FEMALE; HEART ATRIUM; HEART INNERVATION; HEART PROTECTION; HEART VENTRICLE; IMMUNOHISTOCHEMISTRY; MACROPHAGE; NERVE FIBER; NEUROPATHY; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; RADIOIMMUNOASSAY; RAT; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA ANALYSIS; SIGNAL TRANSDUCTION; SMOOTH MUSCLE FIBER; STREPTOZOCIN DIABETES;

ANIMALS; CARDIOMYOPATHIES; DIABETES MELLITUS, EXPERIMENTAL; DOWN-REGULATION; HEART VENTRICLES; IMMUNOHISTOCHEMISTRY; MACROPHAGES, PERITONEAL; MYOCARDIUM; MYOCYTES, CARDIAC; PROTEIN PRECURSORS; RADIOIMMUNOASSAY; RATS; RECEPTORS, VASOACTIVE INTESTINAL PEPTIDE, TYPE II; RECEPTORS, VASOACTIVE INTESTINAL POLYPEPTIDE, TYPE I; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; VASOACTIVE INTESTINAL PEPTIDE;

ANIMALIA;

EID: 32444442070     PISSN: 0302766X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00441-005-0001-7     Document Type: Article

References (40)

1. Adeghate E, Ponery AS, Pallot DJ, Singh J (2001) Distribution of vasoactive intestinal polypeptide, neuropeptide-Y and substance P and their effects on insulin secretion from the in vitro pancreas of normal and diabetic rats. Peptides 22:99-107
2. ATP current in rat atrial myocytes. Am J Physiol Heart Circ Physiol 280:1058-1065
3. Belai A, Lincoln J, Bumstock G (1987) Lack of release of vasoactive intestinal polypeptide and calcitonin gene-related peptide during electrical stimulation of enteric nerves in streptozotocin-diabetic rats. Gastroenterology 93:1034-1040
4. Belai A, Facer P, Bishop A, Polak JM, Burnstock G (1993) Effect of streptozotocin-diabetes on the level of VIP and mRNA in myenteric neurones. Neuroreport 4:291-294
5. Belai A, Calcutt NA, Carrington AL, Diemel LT, Tomlinson DR, Bumstock G (1996) Enteric neuropeptides in streptozotocin-diabetic rats; effects of insulin and aldose reductase inhibition. J Auton Nerv Syst 8:163-169
6. Bertrand G, Puech R, Maisonnasse Y, Bockaert J, Loubatieres-Mariani MM (1996) Comparative effects of PACAP and VIP on pancreatic endocrine secretions and vascular resistance in rat. Br J Pharmacol 117:764-770
7. DeHaven WI, Cuevas J (2002) Heterogeneity of pituitary adenylate cyclase-activating polypeptide and vasoactive intestinal polypeptide receptors in rat intrinsic cardiac neurons. Neurosci Lett 238:45-49
8. Delgado M, Abad C, Martinez C, Juarranz MG, Arranz A, Gomariz RP, Leceta J (2002) Vasoactive intestinal peptide in the immune system: potential therapeutic role in inflammatory and autoimmune disease. J Mol Med 80:16-24
9. Delgado M, Pozo D, Ganea D (2004) The significance of vasoactive intestinal peptide in immunomodulation. Pharmacol Rev 56:249-290
10. Dijkstra CD, Döpp EA, Joling P, Kraal G (1985) The heterogeneity of mononuclear phagocytes in lymphoid organs: distinct macrophage subpopulations in the rat recognized by monoclonal antibodies ED1, ED2 and ED3. Immunology 54:589-599
11. Filipsson K, Sundler F, Hannibal J, Ahren B (1998) PACAP and PACAP receptors in insulin producing tissues: localization and effects. Regul Pept 74:167-175
12. Harmar AJ, Arimura A, Gozes I, Journot L, Laburthe M, Pisegna JR, Rawlings SR, Robberecht P, Said SI, Sreedharan SP, Wank SA, Waschek JA (1998) International Union of Pharmacology. XVIII. Nomenclature of receptors for vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide. Pharmacol Rev 50:265-269
13. Henning RJ, Sawmiller DR (2001) Vasoactive intestinal peptide: cardiovascular effects. Cardiovasc Res 49:27-37
14. Inagaki N, Yoshida H, Mizuta M, Mizuno N, Fujii Y, Gonoi T, Miyazaki J, Seino S (1994) Cloning and functional characterization of a third pituitary adenylate cyclase-activating polypeptide receptor subtype expressed in insulin-secreting cells. Proc Natl Acad Sci U S A 91:2679-2683
15. Ishihara T, Shigemoto R, Mori K, Takahashi K, Nagata S (1992) Functional expression and tissue distribution of a novel receptor for vasoactive intestinal polypeptide. Neuron 8:811-819
16. Klimaschewski L (1997) VIP-a "very important peptide" in the sympathetic nervous system? Anat Embryol 196:269-277
17. Kuncová J, Slavíková J, Reischig J (2003) Distribution of vasoactive intestinal polypeptide in the rat heart: effect of guanethidine and capsaicin. Ann Anat 185:153-161
18. McDonald TP, Dinnis DM, Morrison CF, Harmar AJ (1998) Desensitization of the human vasoactive intestinal peptide receptor (hVIP2/PACAP R): evidence for agonist-induced receptor. Ann NY Acad Sci 865:64-72
19. Miyata A, Sato K, Hino J, Tamakawa H, Matsuo H, Kangawa K (1998) Rat aortic smooth-muscle cell proliferation is bidirectionally regulated in a cell cycle-dependent manner via PACAP/VIP type 2 receptor. Ann NY Acad Sci 865:73-81
20. Nowak TV, Chey WW, Chang TM, Weisbruch JP, Fouquet G (1995) Effect of streptozotocin-induced diabetes mellitus on release of vasoactive intestinal polypeptide from rodent small intestine. Dig Dis Sci 40:828-836
21. Obata K, Itoh N, Okamoto H, Yanaihara C, Yanaihara N, Suzuki T (1981) Identification and processing of biosynthetic precursors to vasoactive intestinal polypeptide in human neuroblastoma cells. FEBS Lett 136:123-126
22. Onuoha GN, Alpar EK, Chukwulobelu R, Nicholls DP (1999) Distributions of VIP, substance P, neurokinin A and neurotensin in rat heart: an immunocytochemical study. Neuropeptides 33:19-25
23. Regalia J, Cai F, Helke C (2002) Streptozotocin-induced diabetes and the neurochemistry of vagal afferent neurons. Brain Res 938:7-14
24. Richardson RJ, Grkovic I, Anderson CR (2003) Immunohistochemical analysis of intracardiac ganglia of the rat heart. Cell Tissue Res 314:337-350
25. Said SI (1986) Vasoactive intestinal peptide. J Endocrinol Invest 9:191-200
26. Said SI, Mutt V (1970) Polypeptide with broad biological activity: isolation from small intestine. Science 169:1217-1218
27. Sano H, Miyata A, Horio T, Nishikimi T, Matsuo H, Kangawa K (2002) The effect of pituitary adenylate cyclase activating polypeptide on cultured rat cardiocytes as a cardioprotective factor. Regul Pept 109:107-113
28. Shetzline MA, Walkers JKL, Valenzano KJ, Premont RT (2002) Vasoactive intestinal polypeptide type-1 receptor regulation. J Biol Chem 277:25519-25526
29. Slavíková J (1997) Distribution of peptide-containing neurons in the developing rat right atrium, studied using immunofluorescence and confocal laser scanning. Neurochem Res 22:1013-1021
30. Steers WD, Mackway-Gerardi AM, Ciambotti J, de Groat WC (1994) Alterations in neural pathways to the urinary bladder of the rat in response to streptozotocin-induced diabetes. J Auton Nerv Syst 47:83-94
31. Straub SG, Sharp GW (1996) A wortmannin-sensitive signal transduction pathway is involved in the stimulation of insulin release by vasoactive intestinal polypeptide and pituitary adenylate cyclase-activating polypeptide. J Biol Chem 271:1660-1668
32. Tamakawa H, Miyata A, Satoh K, Miyake Y, Matsuo H, Arimura A, Kangawa K (1998) The augmentation of pituitary adenylate cyclase-activating polypeptide (PACAP) in streptozotocin-induced diabetic rats. Peptides 19:1497-1502
33. Troger J, Neyer S, Heufler C, Huemer H, Schmid E, Griesser U, Kralinger M, Kremser B, Baldissere I, Kieselbach G (2001) Substance P and vasoactive intestinal polypeptide in the streptozotocin-induced diabetic rat retina. Investig Ophthalmol Vis Sci 42:1045-1050
34. Tsutsumi M, Claus TH, Liang Y, Li Y, Yang L, Zhu J, Dela Cruz F, Peng X, Chen H, Yung SL, Hamren S, Livingston JN, Pan CQ (2002) A potent and highly selective VPAC2 agonist enhances glucose-induced insulin release and glucose disposal. A potential therapy for type 2 diabetes. Diabetes 51:1453-1460
35. Wei Y, Mojsov S (1996) Tissue specific expression of different human receptor types for pituitary adenylate cyclase activating polypeptide and vasoactive intestinal polypeptide: implications for their role in human physiology. J Neuroendocrinol 8:811-817
36. Weihe E, Reinecke M, Forssmann WG (1984) Distribution of vasoactive intestinal polypeptide-like immunoreactivity in the mammalian heart. Interrelation with neurotensin- and substance P-like immunoreactive nerves. Cell Tissue Res 236:527-540
37. Yada T, Sakurada M, Ihida K, Nakata M, Murata F, Arimura A, Kikuchi M (1994) Pituitary adenylate cyclase activating polypeptide is an extraordinarily potent intra-pancreatic regulator of insulin secretion from islet beta-cells. J Biol Chem 269:1290-1293
38. Yung SL, Dela Cruz F, Hamren S, Zhu J, Tsutsumi M, Bloom JW, Caudle M, Roczniak S, Todd T, Lemoine L, MacDougall M, Shanafelt AB, Pan CQ (2003) Generation of highly selective VPAC2 receptor agonists by high throughput mutagenesis of vasoactive intestinal peptide and pituitary adenylate cyclase-activating peptide. J Biol Chem 278:10273-10281
39. Ziegler D (1999) Cardiovascular autonomic neuropathy: clinical manifestations and measurements. Diabetes Rev 7:342-357
40. Zochodne DW, Verge VM, Cheng C, Sun H, Johnston J (2001) Does diabetes target ganglion neurones? Progressive sensory neurone involvement in long-term experimental diabetes. Brain 124:2319-2334